Aligos Therapeutics To Host KOL Event To Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics, Inc. (NASDAQ:ALGS) will host a virtual KOL event to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB). The event will feature Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, and will take place on November 16, 2023. The Phase 1 data are being featured in a late breaking poster session at the Liver Meeting® of the American Association of Liver Disease on November 13, 2023.
November 03, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aligos Therapeutics is hosting a KOL event to discuss the Phase 1 results of its drug candidate ALG-000184 for chronic Hepatitis B. This could potentially impact the company's stock depending on the results discussed.
The announcement of a KOL event to discuss the Phase 1 results of Aligos Therapeutics' drug candidate ALG-000184 could potentially impact the company's stock. The impact will depend on the results discussed during the event and the market's reaction to it. As the event is focused on a specific drug candidate of the company, the relevance is high. The importance is also significant as the results could influence the company's future prospects. The confidence in this analysis is relatively high, based on the information provided in the news.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100